Evidence map›Paper›PMID 34720605›Full record

ArticleJournal of central nervous system disease2021

Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis.

Qi Wu, Qin Wang, Jennifer Yang, Jacob Ws Martens, Elizabeth A Mills, Aiya Saad, Pavani Chilukuri, Catherine A Dowling, Yang Mao-Draayer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of central nervous system disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2021
    Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Current and Future Biomarkers in Multiple Sclerosis.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qi WuDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Qin WangDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0002-2744-6497
Jennifer YangDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Jacob Ws MartensDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Elizabeth A MillsDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Aiya SaadDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Pavani ChilukuriDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Catherine A DowlingDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Yang Mao-DraayerDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.

Funding

University of Michigan Clinical Autoimmunity Center of ExcellenceUM1AI144298 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN, KHANNA, DINESH · 2019 to 2023
$546k
University of Michigan Autoimmunity Center of Excellence, Clinical Research ProgrUM1AI110557 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN · 2014 to 2018
$543k
NIAID NIH HHS UM1 AI110557NIAID NIH HHS UM1 AI144298
6 · The paper itself

Abstract

backgroundThe long-term prognosis of relapsing-remitting multiple sclerosis (RRMS) is usually unfavorable as most patients transition to secondary progressive multiple sclerosis (SPMS) with accumulative disability. A rare form of non-progressive multiple sclerosis (MS) also exists, known as benign MS (BMS or NPMS), which lacks disease progression defined as Expanded Disability Status Scale (EDSS) ≤3 after 15 years of disease onset without treatment. PURPOSE: Our study aims to identify soluble plasma factors predicting disease progression in multiple sclerosis (MS). RESEARCH DESIGN AND STUDY SAMPLE: We utilized Luminex multiplex to analyze plasma levels of 33 soluble factors, comparing 32 SPMS patients to age-, sex-, and disease duration-matched non-progressive BMS patients, as well as to RRMS patients and healthy controls.

resultsPlasma levels of EGF, sCD40L, MCP1/CCL2, fractalkine/CX3CL1, IL-13, Eotaxin, TNFβ/LTα, and IL-12p40 were significantly different between the various types of MS. Plasma sCD40L was significantly elevated in SPMS compared to BMS and RRMS. The combination of MCP1/CCL2 and sCD40L discriminated between RRMS and SPMS. MCP1/CCL2 was found to be the most effective classifier between BMS and RRMS, while BMS was most effectively distinguished from SPMS by the combination of sCD40L and IFNγ levels.

conclusionsThese differences may facilitate personalized precision medicine and aid in the discovery of new therapeutic targets for disease progression through the improvement of patient stratification.

Indexed as

Benign MSmultiple sclerosisrelapsing remitting MSsecondary progressive multiple sclerosissoluble CD40 ligand

Identifiers

PMID34720605
PMCPMC8552403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.